
# **New Effective Renal Protection**








# **Chronic Renal Disease (CRD)**



#### Staging System for Chronic Kidney Disease (CKD)<sup>4</sup>




Step 1: Staging is initially based on fasting plasma creatinine assessed on at least two occasions in the stable patient.

Step 2: Cases are then substaged based on proteinuria and blood pressure.



# CRD Leads to Elevated Phosphorus and Soft Tissue Calcification

- · Chronic renal disease is characterized by retention of phoshate
- Resulting phosporus imbalance leads to secondary hyperparathyroidism
- Increased parathyroid hormone (PTH) mobilizes calcium from the bone and can result in soft tissue calcification
- PTH may also have direct harmful effects on the kidneys



Restriction of phosphorus plays an essential role in curbing renal secondary hyperparathyroidism, soft tissue calcification and progression of renal failure. <sup>5,6</sup>

Phosphate restriction before elevation of serum phophate levels above the normal range may help control the cycle of hyperparathyroidism in CRD.<sup>7</sup>

### Renoprotection through Limitation of Phosphate


#### Main component of Renalzin® is Lantharenol®

Lantharenol® is composed of lanthanum carbonate, a potent new non-calcium- and non-aluminum-based phosphate binder.



Lantharenol® binds phosphate in the gastrointestinal tract to form an insoluble lanthanum salt, rendering the phosphorus indigestible and unable to cross the intestinal wall.

# Renalzin effectively binds dietary phosphate even with normal feline diets<sup>8</sup>



Renalzin® significantly increased fecal elimination and decreased urinary excretion of phosphorus when administered with normal diet, while maintaining palatability.

Result: Shift in phosphorus elimination, effective renoprotection.




Long-term treatment with Renalzin® can enhance quality of life.




### Clinical Studies in Feline Patients Demonstrate Renalzin®'s Beneficial Effects

Renalzin<sup>®</sup> causes significant decreases in phosphate digestibility with both high and lower phosphate diets.<sup>9</sup>



Percentage change in apparent digestibility of phosphorus after supplementation of different feline diets with Renalzin®


#### Decrease in serum phophate levels Clinical field study in cats with CRD<sup>10</sup>



Over a two-months observation period, cats given Renalzin® with standard maintenance diets non-restricted in phosphorus had a trend towards decrease in serum phosphate levels.

# Renalzin® - Safe & Effective Renoprotection

Improvement in clinical examination scores<sup>10</sup> Clinical field study in cats with CRD



Cats given Renalzin® with their normal diet for 2 months showed improvement in general clinical examination parameters as assessed by their veterinarians.

#### Safety

- Renalzin® was demonstrated to be safe when administered up to 10 times the recommended dosing level.
- No signs of intolerability seen during efficacy and safety studies.
- Renalzin® contains a calcium-free and aluminumfree phosphate binder – Lantharenol®.
- Lantharenol® remains in the gastrointestinal tract and systemic absorption is negligible.





## Renalzin<sup>®</sup> Means Compliance – Compliance Means Treatment Success

#### · Every food regimen is possible

Independent of:

- · wet or dry food
- · once or twice daily feeding
- · renal diet or regular food

Renalzin® can be added in every case.

#### Food intake as usual

Neutral taste of Renalzin® ensures that the acceptance of the food given remains unchanged.

In a clinical field study, 85% of cats with CRD given Renalzin® with their normal diet showed improvement or no change in feed intake.<sup>10</sup>

#### Convenience of application

Renalzin® comes in a convenient applicator and is very easy to apply: one pump applies 1 ml



#### Lantharenol® has additional supporting ingredients:

- Kaolin well-known intestinal toxin binder
- Vitamin E acts as a powerful biological antioxidant
- Lulich JP, O'Brien TD, Osborne CA, Polzin DJ. Feline renal failure: questions, answers, questions. Compend Cont Ed Pract Vet 1992, 14(2): 127–151
- Polzin DJ, Osborne CA, Adams LG, Lulich JP. Medical management of feline chronic renal failure. In, Bonagura JD, Kirk RW (eds). Current Veterinary Therapy XI. Philadelphia, PA, Saunders, 1992: 848–853
- 3. Grauer GF. Early detection of renal damage and disease in dogs and cats. Vet Clin Small Anim 2005, 35: 581–596
- 4. International Renal Interest Society (IRIS), 2006
- Rubin SI. Chronic renal failure and its management and nephrolithiasis. Vet Clin Small Anim 1997, 27(6): 1331–1354
- Barber PJ, Rawlings JM, Markwell, Elliott J. Effect of dietary phosphate restriction on renal secondary hyperparathyroidism in the cat. J Small Anim Prac 1999, 40: 62–70.
- Polzin DJ, Osborne CA, Ross S, Jacob F. Dietary management of feline chronic renal failure: where are we know? In what direction are we headed? J Feline Med Surgery 2000, 2: 75–82
- Schmidt B, Delport P, Spiecker-Hauser U. Bay 78–1887, a novel lanthanum-based phosphate binder, decreases intestinal phosphorus absorption in cats. J vet Pharmacol Therap 2006, 29 (Suppl 1): 206-207
- Schmidt B, Spiecker-Hauser U, Gropp J. Effect of Lantharenol® on apparent phosphorus absorption from a conventional feline maintenance diet and a renal diet for cats.
   Proc Soc Nutr Physiol (2008) 17, in press
- 10. Data submitted for publication





